Alpha Cognition Inc
ACOG
주식 순위
#20419
Alpha Cognition Inc., a biopharmaceutical company, engages in the development... Alpha Cognition Inc., a biopharmaceutical company, engages in the development of treatments for patients suffering from neurodegenerative diseases in the United States and Canada. The company's commercial development program includes ZUNVEYL oral tablet formulation for treating Alzheimer's disease. Its pre-clinical development programs comprise ZUNVEYL in combination with memantine for the treatment of moderate-to-severe Alzheimer's disease; ALPHA-1062 sublingual formulation for acute pancreatitis; ALPHA-1062 intranasal formulation for the treatment of cognitive impairment with mild traumatic brain injury; and ALPHA-0602, ALPHA-0702, and ALPHA-0802 programs for the treatment of neurodegenerative diseases, including amyotrophic lateral sclerosis disease and spinal muscular atrophy. The company was founded in 2000 and is headquartered in Vancouver, Canada.
주가
$8.13
마지막 동기화: 2026-10-16
시가총액
$126.27M
변동 (1일)
-3.79%
변동 (1년)
61.63%
국가
US
거래 Alpha Cognition Inc (ACOG)
카테고리
Healthcare
의 시가총액 Alpha Cognition Inc(ACOG)
시가총액: $126.27M
October 2026 기준으로 Alpha Cognition Inc의 시가총액은 $126.27M입니다. 이는 당사 데이터에 따르면 Alpha Cognition Inc이 세계에서 20419th번째로 가치 있는 기업임을 의미합니다. 시가총액은 상장된 회사의 발행 주식 총 시장 가치를 의미하며, 일반적으로 회사의 가치를 측정하는 데 사용됩니다.
2021부터 2026까지 Alpha Cognition Inc의 시가총액 기록
